Saturday, August 9, 2025
Science
No Result
View All Result
  • Login
  • HOME
  • SCIENCE NEWS
  • CONTACT US
  • HOME
  • SCIENCE NEWS
  • CONTACT US
No Result
View All Result
Scienmag
No Result
View All Result
Home Science News Cancer

Nrf2 Emerges as a Central Factor in Osteosarcoma Treatment Resistance

April 21, 2025
in Cancer
Reading Time: 3 mins read
0
fig 1
65
SHARES
592
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT

In the evolving landscape of pediatric oncology, osteosarcoma remains a formidable adversary. As the most prevalent primary malignant bone tumor in children and adolescents, its aggressive biology and resistance to conventional treatments pose significant clinical challenges. Recent scientific breakthroughs have shifted the spotlight onto a transcription factor known as Nuclear factor E2-related factor 2 (Nrf2), revealing a complex duality in its function that profoundly impacts chemoradiotherapy resistance in osteosarcoma.

Nrf2 has long been recognized for its critical role in maintaining cellular redox homeostasis. By regulating the expression of antioxidant genes through the antioxidant response element (ARE), Nrf2 protects normal cells from oxidative damage and environmental toxins. However, in the context of malignancy, this protective mechanism takes on a sinister role. In osteosarcoma cells, aberrant activation and overexpression of Nrf2 establish a survival advantage, safeguarding tumor cells from the cytotoxic effects of chemotherapy and radiotherapy.

One of the principal ways Nrf2 mediates chemoresistance is through the modulation of intracellular drug concentration. It achieves this by inducing the expression of drug transporter proteins belonging to the ATP-binding cassette (ABC) family and reduced folate carrier (RFC) proteins. These efflux pumps effectively lower the accumulation of chemotherapeutic agents such as cisplatin, doxorubicin, and methotrexate within cancer cells, thereby diminishing drug efficacy. This mechanism is further compounded by Nrf2’s ability to enhance cellular detoxification pathways, enabling malignant cells to neutralize and eliminate harmful compounds more efficiently.

ADVERTISEMENT

Beyond drug resistance, Nrf2 orchestrates a robust defense against radiotherapy-induced oxidative stress. Ionizing radiation primarily exerts its tumoricidal effect by generating reactive oxygen species (ROS), which inflict DNA damage and promote cell death. Elevated Nrf2 activity in osteosarcoma cells boosts the production of antioxidant enzymes and DNA repair machinery, allowing these cells to swiftly mitigate ROS damage and repair lethal DNA double-strand breaks. This concerted response not only preserves tumor cell viability but also fosters radioresistance, undermining clinical treatment outcomes.

The intricate regulatory network surrounding Nrf2 involves critical signaling pathways that contribute to osteosarcoma pathophysiology. The Keap1-Nrf2-ARE axis, a well-characterized molecular sensor of oxidative stress, becomes dysfunctional in resistant tumors, leading to persistent Nrf2 activation. Meanwhile, crosstalk with the PI3K/AKT pathway amplifies survival signals and promotes metabolic remodeling, further supporting malignant progression. Autophagy, a cellular recycling process, is also modulated by Nrf2, balancing tumor cell survival and death while influencing susceptibility to therapy. Moreover, emerging evidence highlights interactions between Nrf2 and regulated cell death mechanisms like ferroptosis, underscoring its role not only as a protector but also as a modulator of tumor fate decisions.

Crucially, Nrf2’s influence extends beyond survival pathways to govern tumor proliferation and metastasis. Osteosarcoma cells with upregulated Nrf2 demonstrate metabolic reprogramming favoring anabolic growth and adaption to nutrient-deprived microenvironments. This metabolic flexibility, combined with Nrf2’s promotion of epithelial-to-mesenchymal transition (EMT), facilitates tumor dissemination and secondary colonization. Clinical data correlates high Nrf2 expression levels with poorer patient prognoses and reduced overall survival, firmly establishing its oncogenic potential.

Targeting Nrf2 therapeutically is a daunting endeavor due to its indispensable role in protecting normal tissues from oxidative injury. Nonetheless, the discovery of selective inhibitors such as ML385, which disrupt the Nrf2 pathway, offers a promising avenue to sensitize osteosarcoma cells to conventional therapies. Additionally, natural compounds like oridonin have exhibited efficacy in preclinical models by dampening Nrf2-mediated resistance mechanisms and inducing tumor regression. These approaches symbolize the pioneering efforts to exploit tumor-specific vulnerabilities while minimizing collateral damage.

The quest to unravel the multilayered functions of Nrf2 underscores a paradigm shift in understanding osteosarcoma biology. It invites a nuanced appreciation that while antioxidant defense is vital for physiological homeostasis, its hijacking by cancer cells represents a formidable barrier to treatment success. As research intensifies, focusing on the molecular intricacies of Nrf2 regulation and interaction networks may unlock innovative therapeutic strategies tailored for resistant osteosarcoma subtypes.

Further investigations into the role of Nrf2 in modulating autophagy, ferroptosis, and metabolic plasticity will be critical. These studies promise to delineate the balance between tumor suppression and promotion exerted by Nrf2, guiding the design of combination therapies that strategically disrupt survival pathways. Meanwhile, advancements in drug delivery systems and precision medicine hold potential to translate Nrf2-targeted interventions from bench to bedside.

Ultimately, these insights herald a new era in combating osteosarcoma. By deciphering the molecular underpinnings driving chemoradiotherapy resistance, the scientific community paves the way for more effective and personalized treatment regimens. Harnessing the knowledge of Nrf2’s double-edged impact may revolutionize clinical outcomes for pediatric patients battling this aggressive malignancy, offering hope for improved survival and quality of life.

—

Subject of Research: Chemoradiotherapy resistance mechanisms in osteosarcoma focused on the role of Nuclear factor E2-related factor 2 (Nrf2).

Article Title: Nrf2: A key regulator in chemoradiotherapy resistance of osteosarcoma

News Publication Date: 2024

Web References:
http://dx.doi.org/10.1016/j.gendis.2024.101335

References:
Xianglin Peng, Jing Feng, Han Yang, Ping Xia, Feifei Pu, Nrf2: A key regulator in chemoradiotherapy resistance of osteosarcoma, Genes & Diseases, Volume 12, Issue 4, 2025, 101335.

Image Credits: Genes & Diseases

Keywords: Osteosarcoma, Nrf2, chemoradiotherapy resistance, antioxidant response element, drug efflux, DNA repair, reactive oxygen species, Keap1-Nrf2-ARE pathway, PI3K/AKT signaling, autophagy, ferroptosis, tumor proliferation, metastasis

Tags: antioxidant response element regulationATP-binding cassette transporterscellular redox homeostasis in cancerchemoradiotherapy resistance mechanismschemotherapy and radiotherapy in osteosarcomadrug transporter proteins in cancerNrf2 in osteosarcoma treatment resistancenuclear factor E2-related factor 2overcoming osteosarcoma treatment resistance.oxidative damage in malignant tumorspediatric oncology challengessurvival advantage of tumor cells
Share26Tweet16
Previous Post

Innovative Technique Combines Dye and Fiducial Markers for Precise Pulmonary Nodule Localization

Next Post

Unraveling Lipid Metabolism’s Impact on Breast Cancer Progression and Therapy Resistance

Related Posts

blank
Cancer

Cachexia Index Predicts Gastric Cancer Impact

August 9, 2025
blank
Cancer

Sericin Silver Nanoparticles Combat Colorectal Cancer Effectively

August 9, 2025
blank
Cancer

Immune Checkpoint Inhibitors Linked to Heart Inflammation

August 9, 2025
blank
Cancer

Circulating Hsp70 Signals Early Thoracic Cancer Spread

August 9, 2025
blank
Cancer

Tanshinone IIA Boosts Olaparib Killing Breast Cancer Cells

August 9, 2025
blank
Cancer

Resistance Exercise Boosts Sarcopenia in Breast Cancer

August 9, 2025
Next Post
fig 1

Unraveling Lipid Metabolism's Impact on Breast Cancer Progression and Therapy Resistance

  • Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    27531 shares
    Share 11009 Tweet 6881
  • University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept

    943 shares
    Share 377 Tweet 236
  • Bee body mass, pathogens and local climate influence heat tolerance

    641 shares
    Share 256 Tweet 160
  • Researchers record first-ever images and data of a shark experiencing a boat strike

    507 shares
    Share 203 Tweet 127
  • Warm seawater speeding up melting of ‘Doomsday Glacier,’ scientists warn

    310 shares
    Share 124 Tweet 78
Science

Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!

RECENT NEWS

  • Mulberry Vinegar Fights Cognitive Decline via NF-κB
  • Cognitive Motivation Drives Foreign Language Learning and Use
  • Cross-Vendor Diagnostic Imaging Revolutionized by Federated Learning
  • AI Synthesizes Causal Evidence Across Study Designs

Categories

  • Agriculture
  • Anthropology
  • Archaeology
  • Athmospheric
  • Biology
  • Bussines
  • Cancer
  • Chemistry
  • Climate
  • Earth Science
  • Marine
  • Mathematics
  • Medicine
  • Pediatry
  • Policy
  • Psychology & Psychiatry
  • Science Education
  • Social Science
  • Space
  • Technology and Engineering

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 4,860 other subscribers

© 2025 Scienmag - Science Magazine

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • SCIENCE NEWS
  • CONTACT US

© 2025 Scienmag - Science Magazine

Discover more from Science

Subscribe now to keep reading and get access to the full archive.

Continue reading